Semax Labs
SafetyIs semax safe? what the research actually showsDecades of Russian clinical use, zero FDA approval, and no Western trials. Here's what's actually known about Semax safety, dosed plainly and cited.Updated 2026-07-25Read guideSafetySemax drug interactions: what's known and what isn'tNo formal drug interaction trials exist for Semax. Here's what the mechanistic and Russian clinical literature suggests about real risk, from a safety standpoint.Updated 2026-07-25Read guideSafetySemax long term side effects: what the evidence actually showsNo published long-term human safety trials exist for Semax past a few months. Here's what decades of Russian use and animal data do and don't tell us.Updated 2026-07-25Read guideSafetyDoes Semax cause hair loss? What the evidence actually showsNo published study links Semax to hair loss. We review the safety literature, mechanism data, and what Russian clinical trials reported over 30 years.Updated 2026-07-24Read guideSafetySemax and athlete drug testing: WADA status and detection riskSemax is not on the WADA Prohibited List as of 2024, but its ACTH-like structure and regulatory ambiguity create detection and compliance risks for competitive athletes.Updated 2026-07-24Read guideSafetySemax and blood work: what the research shows and doesn'tNo published human trials document blood marker changes from Semax. Here's what animal studies suggest, why pre-dosing labs matter, and what to monitor.Updated 2026-07-24Read guideSafetySemax contraindications: what the Russian clinical data saysSemax lacks FDA approval and Western trials. Russian clinical use reports pregnancy concerns and peptide sensitivity as primary contraindications.Updated 2026-07-24Read guideSafetySemax in women: what the evidence shows and what's missingMost Semax research used male rodents. Here's what we know about sex-specific mechanisms, pregnancy safety gaps, and real dosing in women.Updated 2026-07-24Read guideSafetySemax side effects: what the clinical record actually showsDecades of Russian clinical use report mild transient irritation in ~5-8% of users. No serious adverse events in peer-reviewed trials. Western replication is absent.Updated 2026-07-24Read guide
Start provider review